Compare · ARGX vs VIGL
ARGX vs VIGL
Side-by-side comparison of argenx SE (ARGX) and Vigil Neuroscience Inc. (VIGL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and VIGL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $48.52B, about 117.2x VIGL ($414.1M).
- Over the past year, ARGX is up 22.3% and VIGL is up 215.7% - VIGL leads by 193.4 points.
- ARGX has hit the wire 3 times in the past 4 weeks while VIGL has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 11 for VIGL).
- Company
- argenx SE
- Vigil Neuroscience Inc.
- Price
- $781.78+0.74%
- $8.06+0.25%
- Market cap
- $48.52B
- $414.1M
- 1M return
- +7.01%
- +0.94%
- 1Y return
- +22.29%
- +215.66%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2022
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Vigil Neuroscience Inc.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Latest ARGX
- argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Latest VIGL
- SEC Form 15-12G filed by Vigil Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vigil Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vigil Neuroscience Inc.
- SEC Form EFFECT filed by Vigil Neuroscience Inc.
- SEC Form EFFECT filed by Vigil Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Vigil Neuroscience Inc.
- Large owner Atlas Venture Fund Xii, L.P. returned 5,836,874 shares to the company (SEC Form 4)
- SEC Form S-8 POS filed by Vigil Neuroscience Inc.
- SEC Form S-8 POS filed by Vigil Neuroscience Inc.
- SEC Form S-8 POS filed by Vigil Neuroscience Inc.